BioNTech Net Worth

BioNTech Net Worth Analysis

BioNTech Target Price Consensus

BioNTech Target Price Projection

BioNTech's current and average target prices are 120.88 and 136.62, respectively. The current price of BioNTech is the price at which BioNTech SE is currently trading. On the other hand, BioNTech's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on BioNTech SE and the information provided on this page.

Know BioNTech's Top Institutional Investors

Note, although BioNTech's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow BioNTech's market capitalization trends

The company currently falls under 'Large-Cap' category with a current market capitalization of 29.05 B.

Project BioNTech's profitablity

The company has Profit Margin (PM) of (0.15) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.02 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.02.

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Evaluate BioNTech's management efficiency

BioNTech SE has return on total asset (ROA) of (0.0124) % which means that it has lost $0.0124 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.024) %, meaning that it created substantial loss on money invested by shareholders. BioNTech's management efficiency ratios could be used to measure how well BioNTech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, BioNTech's Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.07 in 2025, whereas Return On Capital Employed is likely to drop 0.03 in 2025. At this time, BioNTech's Return On Assets are fairly stable compared to the past year.

BioNTech Corporate Filings

BioNTech time-series forecasting models is one of many BioNTech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioNTech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

BioNTech Earnings Estimation Breakdown

The calculation of BioNTech's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of BioNTech is estimated to be -0.830475 with the future projection ranging from a low of -1.439275 to a high of -0.35525. Please be aware that this consensus of annual earnings estimates for BioNTech SE is based on EPS before non-recurring items and includes expenses related to employee stock options.

BioNTech Earnings Projection Consensus

BioNTech Earnings per Share Projection vs Actual

Actual Earning per Share of BioNTech refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering BioNTech SE predict the company's earnings will be in the future. The higher the earnings per share of BioNTech, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

BioNTech Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as BioNTech, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of BioNTech should always be considered in relation to other companies to make a more educated investment decision.

BioNTech Quarterly Analyst Estimates and Surprise Metrics

BioNTech Corporate Management

Additional Tools for BioNTech Stock Analysis